Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

N/A

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 2(4)

N/A(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03489629Phase 2Completed

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

Role: collaborator

NCT02475434Not ApplicableCompleted

Use of Human Milk Cream to Decrease Length of Stay in Extremely Premature Infants

Role: collaborator

NCT02860702Not ApplicableCompleted

Exclusive Human Milk Feeding in Infants With Single Ventricle Physiology

Role: collaborator

NCT02811263Phase 3Completed

High-dose Erythropoietin for Asphyxia and Encephalopathy

Role: collaborator

NCT00879437Phase 2Completed

Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma

Role: collaborator

NCT01182350Phase 2Terminated

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Role: collaborator

NCT01349192Phase 2Terminated

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

Role: collaborator

All 7 trials loaded